Weixue Huang

780 total citations
39 papers, 544 citations indexed

About

Weixue Huang is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Weixue Huang has authored 39 papers receiving a total of 544 indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Molecular Biology, 13 papers in Oncology and 6 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Weixue Huang's work include Protein Degradation and Inhibitors (10 papers), Ubiquitin and proteasome pathways (8 papers) and Cancer-related Molecular Pathways (5 papers). Weixue Huang is often cited by papers focused on Protein Degradation and Inhibitors (10 papers), Ubiquitin and proteasome pathways (8 papers) and Cancer-related Molecular Pathways (5 papers). Weixue Huang collaborates with scholars based in China, United States and Thailand. Weixue Huang's co-authors include Ke Ding, Hua Zhou, Zhen Wang, Pei Luo, Xiaomei Ren, Derui Liu, Xiuling Cai, Zhifeng Zhang, Xuecong Ren and Liang Liu and has published in prestigious journals such as Journal of the American Chemical Society, SHILAP Revista de lepidopterología and Accounts of Chemical Research.

In The Last Decade

Weixue Huang

36 papers receiving 537 citations

Peers

Weixue Huang

ONCOL

PFM

HEMAT

Nadine El Banna France

Alejandra Gomez‐Cadena Switzerland

Fatemeh Ahmadipour Malaysia

A.M. Joubert South Africa

Nirupama Gupta United States

Hyeoncheol Kim United States

Eunhye Kim South Korea

Chandrima Sinha United States

Lijun Zhu China

Nadine El Banna France

Weixue Huang

244 ×0.7

51 ×0.6

ONCOL

44 ×1.0

41 ×1.0

PFM

18 ×0.5

HEMAT

Citations per year, relative to Weixue Huang Weixue Huang (= 1×) peers Nadine El Banna

Countries citing papers authored by Weixue Huang

Since Specialization

Citations

This map shows the geographic impact of Weixue Huang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Weixue Huang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Weixue Huang more than expected).

Fields of papers citing papers by Weixue Huang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Weixue Huang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Weixue Huang. The network helps show where Weixue Huang may publish in the future.

Co-authorship network of co-authors of Weixue Huang

This figure shows the co-authorship network connecting the top 25 collaborators of Weixue Huang. A scholar is included among the top collaborators of Weixue Huang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Weixue Huang. Weixue Huang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Yang, Yayuan, Jie Wang, Ping Zhang, et al.. (2025). The design and synthesis of selective and potent selenium-containing KRASG12D inhibitors. European Journal of Medicinal Chemistry. 298. 118004–118004.

Ding, Ke, Yupeng Li, Yang Zhou, & Weixue Huang. (2025). Chemical Adaptation in Drug Discovery: The Medicinal Chemistry Journey of Olverembatinib and Limertinib in Overcoming Kinase Drug Resistance. Accounts of Chemical Research. 58(20). 3195–3209.

Chang, Yu‐Sun, Weixue Huang, Wenyan Liu, et al.. (2025). Discovery of YJZ5118: A Potent and Highly Selective Irreversible CDK12/13 Inhibitor with Synergistic Effects in Combination with Akt Inhibition. Journal of Medicinal Chemistry. 68(6). 6718–6734.

Duan, Liping, Weixue Huang, Jiangnan Zheng, et al.. (2025). O-Cyanobenzaldehydes Irreversibly Modify Both Buried and Exposed Lysine Residues in Live Cells. Journal of the American Chemical Society. 147(14). 11955–11963. 5 indexed citations

Zhang, Hongjin, Jianbo Wu, Ying Zhang, et al.. (2024). Design, synthesis and evaluation of thieno[3,2-d]pyrimidine derivatives as novel potent CDK7 inhibitors. Bioorganic Chemistry. 148. 107456–107456. 3 indexed citations

Li, Huifan, Yihan Chen, Fengtao Zhou, et al.. (2024). Discovery of LHF418 as a new potent SOS1 PROTAC degrader. Bioorganic & Medicinal Chemistry. 103. 117661–117661. 4 indexed citations

Parolia, Abhijit, Yihan Liu, Yuanyuan Qiao, et al.. (2024). Discovery of LLC0424 as a Potent and Selective in Vivo NSD2 PROTAC Degrader. Journal of Medicinal Chemistry. 67(9). 6938–6951. 13 indexed citations

Meng, Qingyuan, Weixue Huang, Meiru Song, et al.. (2024). Design and Synthesis of Novel Macrocyclic Derivatives as Potent and Selective Cyclin-Dependent Kinase 7 Inhibitors. Journal of Medicinal Chemistry. 67(8). 6099–6118. 4 indexed citations

Liu, Rong, Xiaomei Ren, Fengtao Zhou, et al.. (2024). Discovery of 5-aminopyrido[2,3-d]pyrimidin-7(8H)-one derivatives as new hematopoietic progenitor kinase 1 (HPK1) inhibitors. European Journal of Medicinal Chemistry. 269. 116310–116310. 5 indexed citations

10.

Zhou, Licheng, Yu‐Sun Chang, Rahul Mannan, et al.. (2024). Discovery of ZLC491 as a Potent, Selective, and Orally Bioavailable CDK12/13 PROTAC Degrader. Journal of Medicinal Chemistry. 67(20). 18247–18264. 8 indexed citations

11.

Li, Chungen, Yihan Chen, Weixue Huang, et al.. (2024). Structure-Based Design of “Head-to-Tail” Macrocyclic PROTACs. SHILAP Revista de lepidopterología. 4(12). 4866–4882. 8 indexed citations

12.

Chen, Zhiyuan, Meiying Zhang, Weixue Huang, et al.. (2024). Mechanisms of acquired resistance to HER2-Positive breast cancer therapies induced by HER3: A comprehensive review. European Journal of Pharmacology. 977. 176725–176725. 11 indexed citations

13.

Gajjala, Prathibha R., Yihan Liu, Manjot Bal, et al.. (2024). Discovery of the first selective and potent PROTAC degrader for the pseudokinase TRIB2. European Journal of Medicinal Chemistry. 281. 117016–117016. 3 indexed citations

14.

Liu, Wenyan, Yu Bai, Licheng Zhou, et al.. (2023). Discovery of LWY713 as a potent and selective FLT3 PROTAC degrader with in vivo activity against acute myeloid leukemia. European Journal of Medicinal Chemistry. 264. 115974–115974. 13 indexed citations

15.

Li, Chungen, Yuanyuan Qiao, Xia Jiang, et al.. (2023). Discovery of a First-in-Class Degrader for the Lipid Kinase PIKfyve. Journal of Medicinal Chemistry. 66(17). 12432–12445. 10 indexed citations

16.

Song, Zhiqiang, Yu Bai, Sheng He, et al.. (2023). Discovery of AXL Degraders with Improved Potencies in Triple-Negative Breast Cancer (TNBC) Cells. Journal of Medicinal Chemistry. 66(3). 1873–1891. 17 indexed citations

17.

Zhou, Jin, Weixue Huang, Sunday Solomon Josiah, et al.. (2023). Neuronal K+-Cl- cotransporter KCC2 as a promising drug target for epilepsy treatment. Acta Pharmacologica Sinica. 45(1). 1–22. 26 indexed citations

18.

Chang, Yu, Jean C. Tien, Zhen Wang, et al.. (2022). Discovery of a Highly Potent and Selective Dual PROTAC Degrader of CDK12 and CDK13. Journal of Medicinal Chemistry. 65(16). 11066–11083. 48 indexed citations

19.

Wang, Zhen, et al.. (2022). Targeting the Non-Catalytic Functions: a New Paradigm for Kinase Drug Discovery?. Journal of Medicinal Chemistry. 65(3). 1735–1748. 28 indexed citations

20.

Yuan, Shuguang, Lian Wu, Lingqia Su, et al.. (2020). Structure-guided engineering of a Thermobifida fusca cutinase for enhanced hydrolysis on natural polyester substrate. Bioresources and Bioprocessing. 7(1). 30 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact